Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome
| Autor: | Norman B, Gaylis, Angela, Ritter, Scott A, Kelly, Nader Z, Pourhassan, Meenakshi, Tiwary, Jonah B, Sacha, Scott G, Hansen, Christopher, Recknor, Otto O, Yang |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Immunosuppression Therapy
Microbiology (medical) immunosuppression Receptors CCR5 Clinical Trials and Supportive Activities Evaluation of treatments and therapeutic interventions COVID-19 leronlimab Biological Sciences CC Medical and Health Sciences Microbiology Infectious Diseases Clinical Research 6.1 Pharmaceuticals Chemokines CC Receptors Humans Chemokines long COVID CCR5 |
| Zdroj: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol 75, iss 7 |
| ISSN: | 1537-6591 1058-4838 |
| DOI: | 10.1093/cid/ciac226 |
| Popis: | In an exploratory trial treating “long COVID” with the CCR5-binding antibody leronlimab, we observed significantly increased blood cell surface CCR5 in treated symptomatic responders but not in nonresponders or placebo-treated participants. These findings suggest an unexpected mechanism of abnormal immune downmodulation in some persons that is normalized by leronlimab. Clinical Trials Registration. NCT04678830. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|